Blog

E-Motion™ 180E systems now eligible for up to $170,000 in per-unit government vouchers-driving large-scale electrification of commercial fleets in California

Key Highlights

• Vision Marine’s E-Motion™ 180E propulsion kits approved under California’s CORE (Clean Off-Road Equipment) program

• Up to $170,000 per vessel in state-funded vouchers available for qualifying fleet operators

• Applies to both new electric boat builds and retrofit conversions using Vision Marine’s certified installers

• California market includes approximately 4,400 commercially operated vessels across sectors such as ferries, harbor patrol, tour boats, rentals, and service craft

• Approval aligns with broader industry momentum toward electrification, strengthening Vision Marine’s market position

MONTREAL, QC / ACCESS Newswire / June 18, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR), a developer of high-performance electric marine propulsion systems, announced today that its flagship E-Motion™ 180E powertrain has been approved for inclusion in California’s CORE (Clean Off-Road Equipment) Voucher Incentive Project.

This approval makes Vision Marine’s propulsion kits eligible for point-of-sale vouchers of up to $170,000 per unit, substantially reducing the cost of adopting electric propulsion for organizations modernizing their fleets.

“This represents a major milestone for Vision Marine, significantly enhancing our market position and accelerating our ability to drive widespread adoption of electric propulsion technology,” said Alexandre Mongeon, CEO of Vision Marine Technologies.

California: A Strategic Market for Marine Electrification

California operates one of the largest and most dynamic commercially operated marine sectors in North America. With approximately 4,400 vessels in use across ferry services, water taxis, harbor patrol, tour operations, and rental businesses, the state presents a significant opportunity for electrification. Many of these segments are actively seeking clean alternatives to gas and diesel propulsion due to emissions regulations and increasing demand for quieter, lower-maintenance vessels.

Vision Marine’s E-Motion™ 180E system-now listed under CORE-offers a compliant, high-performance solution for operators upgrading existing boats or commissioning new electric vessels.

Market Impact and Sales Potential

With this approval, Vision Marine can now offer its E-Motion™ 180E propulsion kits to eligible buyers with substantial financial support from the CORE program. Both new electric vessels and repower conversions are supported when completed by certified Vision Marine technicians and installers.

As the only 180 HP continuous electric powertrain listed under CORE, Vision Marine stands to benefit from increased demand across a wide range of commercial use cases. The company’s commercial readiness, field-tested product, and established presence in California position it well to respond to immediate regional fleet electrification needs.

This milestone also comes as the global marine industry rapidly shifts toward clean propulsion. The combination of policy-driven funding and organic market demand creates a powerful tailwind for Vision Marine Technologies.

“California has long been a bellwether for clean technology adoption,” added Mongeon. “Our CORE approval enhances our visibility and competitiveness in this key market, while reinforcing our ability to scale as electrification expands across North America.”

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a leader in high-performance electric marine propulsion. Its flagship E-Motion™ 180E system delivers 180 HP of continuous power through a fully integrated, scalable electric powertrain platform. Built for reliability and commercial-grade use, Vision Marine’s solutions serve OEMs, fleet operators, government agencies, and rental services across North America.

For more information, visit: www.visionmarinetechnologies.com

About the CORE Program

The Clean Off-Road Equipment (CORE) Voucher Incentive Project is administered by the California Air Resources Board (CARB) and funded by the state’s Cap-and-Trade program. CORE provides point-of-sale vouchers that help reduce the upfront cost of zero-emission off-road equipment, including marine technologies. The program is designed to accelerate the adoption of cleaner equipment and support California’s climate and air quality goals.

To learn more, visit: www.californiacore.org

Forward-Looking Statements

Certain statements in this press release, including, but not limited to, statements regarding the anticipated benefits of the exclusive supply agreement, market expansion, and future events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Vision Marine disclaims any obligation to update these statements except as required by law. Actual results may differ materially from those expressed or implied. For a detailed discussion of these risks, refer to Vision Marine’s Annual Report on Form 20-F for the year ended August 31, 2024, and other periodic filings with the SEC. Vision Marine does not undertake any obligation to update or revise forward-looking statements other than as required by law.

Investor Relations Contact:

Vision Marine Technologies Inc.
Bruce Nurse – Investor Relations
bn@v-mti.com
(303) 919-2193

Website: visionmarinetechnologies.com
Twitter: @marine_vision
Facebook: @VisionMarineTechnologies
Instagram: @visionmarine.technologies
YouTube: @VisionMarineTechnologies

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / June 18, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF) (“Organto” or the “Company“) today announced it plans to complete a non-brokered private placement of up to 4,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit (the “Private Placement“), with each Unit consisting of one Common Share in the capital of the Company (a “Common Share“) and one-half common share purchase warrant of the Company (a “Warrant“).

Each full Warrant shall entitle the holder thereof to acquire one Common Share (a” Warrant Share“) at a price per Warrant Share of C$0.35 for a period of 18 months from the closing date of the Private Placement.

“We’re very pleased with our operational performance, having realized first quarter sales growth of 193.5%, gross profit dollar growth of 298.1%, our lowest cash operating costs as a percentage of sales in our history and our first-ever positive EBITDA quarter. Our business has continued to accelerate through the second quarter, which is quite encouraging, and we believe is a reflection of the strong momentum in our business. These results are the direct outcome of the extensive restructuring and strategic realignment we’ve executed over the past 18 months, laying a solid foundation for sustained growth, stability, and a clear path to profitability. With our continued growth and improvement in our share price, we believe it is prudent to complete this Private Placement as we conservatively manage our balance sheet.” commented Steve Bromley, Chair and Chief Executive Officer.

The Company may pay finders’ fees in connection with the Private Placement. The net proceeds from the Private Placement will be used to fund general working capital.

Certain directors and officers of the Company may acquire securities under the Private Placement. Any such participation would be considered to be a “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101“). The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any units issued to or the consideration paid by such persons will exceed 25% of the Company’s market capitalization.

Completion of the Private Placement will be subject to the prior approval of the TSX Venture Exchange as well as all other requisite corporate, regulatory and security holder approvals, as applicable. Further, all securities issued pursuant to the Private Placement described above will be subject to a minimum hold period of four months and one day from their date of issuance. There can be no assurance that the Company will be successful in completing the Private Placement.

ON BEHALF OF THE BOARD

Steve Bromley
Chairman and CEO

For more information, contact:

Investor Relations
John Rathwell, Senior Vice President, Investor Relations & Corporate Development
647 629 0018
info@organto.com

ABOUT ORGANTO

Organto is a leading provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-lighter business model to serve a growing socially responsible and health-conscious consumers. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law, including without limitation, Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that the impact of restructuring and realignment efforts was a key driver of its first quarter results; and Organto’s belief it is prudent to complete this Private Placement as the Company conservatively manages its balance sheet. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, without limitation, the assumption that the Company will be able to complete the Private Placement and obtain all regulatory and requisite approvals in a timely manner and on acceptable terms. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in forward-looking statements in this news release include, among others, regulatory risks; risks related to market volatility and economic conditions; risks related to unforeseen delays; and risks that necessary financing will be unavailable when needed. For further information on these and other risks and uncertainties that may affect the Company’s business, see the “Risks and Uncertainties” and “Forward-Looking Statements” sections of the Company’s annual and interim management’s discussion and analysis filings with the Canadian securities regulators, which are available under the Company’s profile at www.sedarplus.ca. Except as required by law, Organto does not assume any obligation to release publicly any revisions to forward-looking statements contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.

Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA (https://www.today.com/health/coronavirus/new-covid-variant-nb181-nimbus-symptoms-rcna212304).

Nimbus has been rising globally since Spring according to WHO (https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf).

Nimbus causes “razor-sharp” sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.

Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.

Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.

Recently, the Influenza A H5N1 virus from a dairy worker in Michigan was found to be capable of airborne transmission in a ferret animal model ^[1] (https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.

Additionally, a new genotype of H5N1 in Cambodia has caused four fatalities and fifth severe infection as of today (https://www.cidrap.umn.edu/avian-influenza-bird-flu/h5n1-avian-flu-infects-fifth-patient-cambodia).

NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.

NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.

Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.

NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.

COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.

NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.

NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.

NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.

“NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “We have US-based cGMP manufacturing capabilities already set up as well.”

Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.

Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).

Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.

The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

---

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Influencer Luke Parry and entrepreneur Andrea Harris Jr. have officially announced a strategic business partnership that aims to reshape the digital landscape. With plans to launch a series of ventures spanning fashion, social technology and influencer marketing, the duo intends to capitalize on some of the fastest-growing sectors in today’s economy.

The collaboration marks a significant milestone for both Parry and Harris Jr., combining creative influence with operational expertise to build what they describe as “a portfolio of brands designed for the future of consumer behavior.”

A Digital-Era Alliance

Parry, known for his cinematic content, emotional storytelling and influential presence across social platforms, brings a powerful cultural pulse to the partnership. Harris Jr., a strategist and product developer with a background in early-stage startups and brand architecture, brings the operational clarity and business infrastructure necessary to scale quickly.

“We’re not just launching products-we’re launching ecosystems,” Harris Jr. said. “Everything we do is designed to connect, convert and cultivate long-term consumer relationships.”

The partnership will center around three key verticals: fashion, dating and digital influence. Each reflects both the cultural relevance of their personal brands and the broader economic trends fueling growth in these industries.

Targeting High-Growth Markets

The fashion sector is expected to exceed $1.2 trillion globally by 2027, with significant growth coming from direct-to-consumer models, gender-fluid design and sustainability-focused brands. Parry and Harris Jr. intend to leverage this momentum by launching a fashion brand that centers individuality, self-expression and eco-conscious production.

“The fashion industry is overdue for reinvention,” Parry said. “Consumers want transparency, story and design they can see themselves in. We’re going to deliver that.”

Equally high on their agenda is the dating and relationship technology space, which has seen explosive demand in recent years. According to Statista, the global online dating market is projected to surpass $12 billion by 2030, fueled by younger users seeking more personalized, secure and experience-driven platforms.

Parry and Harris Jr. plan to launch a new dating app that focuses on compatibility, conversation and community-pushing back against the often impersonal swipe-based culture of traditional apps.

“We’re creating something that fosters genuine connection,” Harris Jr. said. “This isn’t gamification. It’s human-first technology.”

Influencer Marketing 2.0

In addition to launching consumer-facing products, the pair intends to build out a new model for influencer marketing-one that prioritizes authenticity, long-term partnerships and co-creation.

With global influencer marketing spend projected to reach $32 billion by 2026, they see an opportunity to set a new standard. The partnership includes plans to develop proprietary tools that connect creators with brands through transparent, equity-based relationships.

“We understand this space from both sides,” Parry said. “We’ve been the talent. We’ve built the content. Now we’re building the infrastructure.”

The goal is to support emerging influencers while also helping legacy brands connect to new audiences more effectively.

Designed for Longevity

While the ventures are still in early stages, both founders emphasized that the long-term vision is to build enduring brands-not momentary hype.

Each business under their collaboration will follow a phased launch strategy, with beta testing and community involvement playing a central role in development. The duo has already begun assembling a cross-disciplinary advisory team of technologists, designers and brand operators.

“We’re playing the long game,” Harris Jr. said. “This is about solving real problems and building value at scale.”

Consumer-Centric, Value-Driven

Whether in fashion, dating or digital influence, the partners share a deep focus on user experience, ethical practices and cultural relevance. They aim to build not just brands-but belief systems that consumers can trust and participate in.

By staying agile and focused on underserved markets, they believe they can create category-defining experiences that resonate with a new generation of consumers.

Looking Ahead

As anticipation builds, Parry and Harris Jr. will spend the next several months developing brand strategy, platform infrastructure and early partnerships ahead of phased launches beginning in 2026.

Public announcements and product previews are expected later this year, with early access opportunities available to subscribers through their forthcoming platform.

“This is the future of brand-building,” Parry said. “It’s bold. It’s personal. And it’s just the beginning.”

About Luke Parry
Luke Parry is a digital creator and cultural voice known for his emotional storytelling and distinctive visual style. His content has garnered a loyal following across multiple platforms, and he is widely regarded as one of the next-generation leaders in content-driven commerce.

About Andrea Harris Jr.
Andrea Harris Jr. is an entrepreneur, strategist and advisor with a background in building scalable businesses across technology, fashion and consumer marketing. He specializes in brand incubation, digital infrastructure and venture growth.

Contact:

Jake Bodiford
mgmt@northregia.com

SOURCE: Harris & Parry LLP

View the original press release on ACCESS Newswire

Need a Ride to Your Medical Appointment? Diamond Care Transportation Offers Safe, On-Time NEMT Services for Seniors and Disabled Patients in South Carolina

GREENVILLE, SOUTH CAROLINA / ACCESS Newswire / June 17, 2025 / Diamond Care Transportation is proud to offer safe, reliable, and wheelchair-accessible Non-Emergency Medical Transportation (NEMT) for seniors, disabled individuals, and patients who need help getting to medical appointments. Based in South Carolina, Diamond Care is now serving Florida, Maryland, and Washington, D.C., as well.

If you or a loved one needs a ride to a doctor’s office, hospital, physical therapy, dialysis center or clinic, Diamond Care makes it easy. No long wait times, no confusion – just caring drivers, clean vehicles, and dependable service you can count on.

What We Offer:

• Wheelchair-accessible vehicles for any mobility level

• Friendly, trained, and CPR-certified drivers

• On-time pickup and drop-off

• Recurring or one-time ride options

• Service from home, nursing home or medical facility

“We believe no one should miss medical care because they can’t get there,” said a representative from Diamond Care. “That’s why we go above and beyond to make sure every patient arrives safely and on time – with care, dignity, and comfort.”

Now Booking NEMT Rides in:

• South Carolina (including Greenville, Columbia, and Charleston)

• Florida (Miami, Tampa, Orlando, Jacksonville)

• Washington State (Seattle, Spokane, Tacoma)

• Maryland (Baltimore, Rockville, Silver Spring)

• Washington, D.C.

Whether it’s a regular appointment or an urgent follow-up, Diamond Care is your partner in health transportation. We help seniors and individuals with disabilities get the care they need – without stress.

Need a Non Emergency Medical Ride to the Doctor? Diamond Care Transportation is Here to Help!

Ready to Book a Ride?

Call Now: +1 (864) 335-9824
Email: info@diamondcaretransportation.com
Website: https://diamondcaretransportation.com

We’re available to answer questions and schedule rides – whether it’s for tomorrow or next week. Let Diamond Care Transportation help you get there safely.

About Diamond Care Transportation

Diamond Care Transportation provides Non-Emergency Medical Transportation (NEMT) with a focus on wheelchair transport, senior care, and disability support. We proudly serve patients across South Carolina, Florida, Washington, Maryland, and D.C., offering trusted service that puts your comfort and health first.

CONTACT: info@diamondcaretransportation.com

SOURCE: Diamond Care Transportation

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / New to The Street, a leading multi-platform media brand for business and financial television, proudly announces the signing of Backstage (NASDAQ:BKS) to an exclusive 12-part national media series.

This powerful media rollout will include monthly long-form interviews, earned media coverage, national television commercials, and Times Square outdoor billboards, reaching over 220 million homes weekly through New to The Street‘s distribution across Bloomberg, Fox Business as sponsored programming, and its fast-growing 2.7M+ subscriber YouTube channel.

Backstage will be featured across all New to The Street platforms as an “Opportunity To Consider™”, with full editorial support and visibility as the company pioneers real-world utility and mainstream adoption of tokenized entertainment through $BKS.

With partnerships already underway across music, sports, and live events, Backstage is rapidly building one of the most comprehensive ecosystems in Entertainment 3.0, positioning itself as a global innovator in tokenized real-world assets (RWA) in the entertainment sector.

“Backstage is unlocking a new era for fans, artists, and event organizers,” said Vince Caruso, CEO of New to The Street. “We’re excited to amplify their story and give them national visibility as they reshape the future of live experiences through digital infrastructure and Web3 technology.”

The campaign begins this month, with first filming in June, followed by a series of national T.V. broadcasts and NYC-based investor and industry events.

About Backstage (NASDAQ:BKS):
Backstage is an Entertainment 3.0 platform built for fans, artists, and event organizers. It enables users to book tickets, hotels, and flights while earning and spending $BKS tokens. Focused on real-world utility and mainstream adoption, Backstage is shaping the future of live experiences-where fans don’t just follow the crowd, they drive it. For the first time, artists and event organizers can capture value from the parallel economy their events generate-hotels, travel, local spending, and digital engagement-transforming previously untapped influence into new revenue streams.

About New to The Street:
New to The Street is a premier financial media platform combining sponsored television programming, earned media coverage, and iconic outdoor advertising. With content distributed on Bloomberg, Fox Business, and YouTube, the platform helps public and private companies reach investors, media, and consumers with unmatched scale and credibility.

Media Contact:

Alessio Piras
ap@ BACKSTAGE.GLOBAL

Monica Brennan
monica@newtothestreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO

STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective June 18, 2025, following a distinguished 20-year term. During his tenure, Dr. Hayward was instrumental in transforming the Company’s proprietary DNA production and detection technologies into commercial platforms, thereby establishing the foundation for Applied DNA’s current market offerings.

Furthermore, the Board of Directors of Applied DNA has appointed Judy Murrah to the roles of Chairperson, Board Director, and Chief Executive Officer in addition to retaining her current position as President. Ms. Murrah will lead the executive management team, which comprises Clay Shorrock, Chief Legal Officer and President of LineaRx, the Company’s biotherapeutics subsidiary, and Beth Jantzen, Chief Financial Officer.

With over a decade of operational leadership at Applied DNA, Ms. Murrah has been influential in driving product commercialization, business scaling, and, more recently, the launch of the Company’s GMP-compliant DNA manufacturing capabilities. She was previously with Symbol Technologies (“Symbol”), where she played key roles in the company’s growth from an early-stage company to an enterprise with approximately $2 billion in revenue and 5,000 employees, holding successive Vice President positions across Sales, Marketing, and Information Technology. Following Symbol’s acquisition by Motorola, Inc. (“Motorola”), she held strategic leadership roles at Motorola, overseeing critical financial management, quality, and program management initiatives during significant business transformations, mergers, acquisitions, and divestitures. Ms. Murrah is an inventor on 14 U.S. patents and holds an MBA from Harvard Business School.

Board Director Robert C. Catell stated, “On behalf of all the employees of the Company and the Board of Directors, I offer sincere thanks to Jim for his many years of scientific innovation, personal contribution, and passion he brought to Applied DNA. His accomplishments and impact are wide-ranging and will endure with the Applied DNA team and the local Long Island community.”

Continued Mr. Catell, “Judy has played an increasingly key role in recent years and has helped to grow who we are today as a company. Applied DNA is poised for opportunity with an established biotherapeutic manufacturing capability that we believe is proven to address the manufacturing challenges identified by the industry. Driving it to deployment and scale with customers, partners, and regulators is our next mission, and the Board is confident that Judy’s leadership will put the Company on the best path forward to maximize long-term shareholder value.”

Added Ms. Murrah, “I am honored to take on the Chairperson and CEO roles and lead our associates and Applied DNA forward at this important inflection point, as we focus on our most promising aspects of our businesses, drive increased operating efficiency, and navigate the current macro environment.”

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using the polymerase chain reaction (“PCR”) to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase (“RNAP”) for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.

Visit adnas.com for more information. Follow us on X and LinkedIn.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company’s expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the ability of Ms. Judy Murrah to successfully replace Dr. James Hayward as Chairperson and CEO of the Company, its goal to position the Company for long term-growth and value creation and the potential to achieve that goal and the future success of its Linea DNA and Linea IVT platforms.. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and/or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing the LineaDNA and/or IVT platforms approved for therapeutic use, the ability of the Company’s common stock to remain listed on Nasdaq as well as various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Applied DNA Sciences Contact:

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Web: https://investors.adnas.com/

SOURCE: Applied DNA Sciences, Inc.

View the original press release on ACCESS Newswire

Head to Toe Healthcare is excited to announce that it is expanding its shockwave therapy services.

TUCSON, AZ / ACCESS Newswire / June 17, 2025 / Head to Toe Healthcare, PLC, led by founder and medical director Dr. Alan Shih, has announced the expansion of its shockwave therapy services, bringing globally informed, non-invasive treatment options to more patients in Southern Arizona.

This milestone comes on the heels of Dr. Shih’s recent participation in the 25th World Congress of the International Society for Medical Shockwave Treatment, held in South Korea. There, he engaged with leading practitioners and researchers to deepen his understanding of the fast-evolving field of shockwave therapy and its growing potential across multiple areas of medicine.

“Attending the World Congress was a reminder that the U.S. still has a lot of catching up to do in this space,” said Dr. Shih. “In Europe and Asia, shockwave therapy is a standard option for many conditions. I’m committed to bringing those advancements here to Tucson, to evolve faster than the average and offer my patients the best care available.”

Shockwave therapy, originally developed as a derivative of lithotripsy (a treatment for kidney stones), uses high-energy sound waves to stimulate healing in musculoskeletal tissues. The treatment is completely non-invasive (the skin is not pierced) and has been shown to decrease scar tissue, improve microcirculation, and accelerate recovery times, often without the need for surgery.

At Head to Toe Healthcare, Dr. Shih primarily utilizes shockwave therapy to treat chronic conditions such as Achilles tendonitis and plantar fasciitis, but he is also pioneering its use in other challenging cases, including neuropathy, an area of his clinical expertise.

One of the most appealing aspects of the treatment is its efficacy. When Dr. Shih recommends that his patients engage in the shockwave procedure, it takes roughly 10-15 minutes, once a week, over a span of four weeks in many cases. “Many report feeling significant relief even after the first treatment. Some have dealt with pain for years, and now they’re walking out of here feeling better than they thought possible.”

According to a recent article by the Journal of the American Medical Association, it usually takes around 17 years for evidence to change practice within the medical field delay Dr. Shih finds unacceptable. “If we wait that long, we’re doing our patients a disservice,” he said. “My goal is to constantly evaluate what’s working globally and bring it into practice today, not tomorrow.”

With this latest expansion, Dr. Shih and his team are actively pursuing additional applications of shockwave therapy and are focused on refining treatment protocols for neuropathy and other difficult-to-treat conditions. The healthcare center is also gathering ongoing patient feedback to better measure long-term outcomes and push the frontier of what’s possible with the therapy.

Dr. Shih’s dedication to lifelong learning and innovation has earned him praise throughout Tucson’s medical community, and his patients are feeling the results.

“It’s been astonishing to see our patients getting better after treating them with shockwave therapy,” says Dr. Shih. “My patients are getting better at a much faster rate without the need for surgery. Some of the people I have treated have been suffering for years, and the use of shockwave has allowed them to feel much better, something they didn’t think was possible.”

“It’s been astonishing to see our patients getting better after treating them with shockwave therapy,” said Dr. Shih. “We’re seeing improvements that would typically take months, if not require surgery, happen within weeks. That’s the kind of impact every doctor dreams of making.”

As Head to Toe Healthcare continues to grow its offerings, Dr. Shih remains focused on one mission: providing effective, evidence-based, and future-forward care for every patient who walks through the door.

Media Contact : Dr Alan Shih
Email : hang10@headtotoehealthcare.org
https://headtotoehealthcare.org/
(520) 545-0202

SOURCE: Dr Alan Shih

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / EquityMultiple, a real estate investment platform for accredited investors, recently released its comprehensive mid-year market outlook examining how rapidly shifting U.S. trade policy is creating both challenges and opportunities across commercial real estate markets.

The report, titled “2025 Second Half Outlook: Market Trends & Voice of the Investor Survey Results,” analyzes the impact of new tariffs on the four core commercial real estate asset classes and provides strategic guidance for investors navigating heightened market volatility. EquityMultiple notes that while tariffs on building materials could present construction challenges, a reduction in new supply competition could benefit existing properties and create opportunities.

The platform’s thesis is straightforward: taking stock of one’s own risk tolerance and diversifying whenever possible is the most prudent approach to investing in uncertain times.

Economic Backdrop Drives Strategic Shifts

The outlook comes as investors grapple with the economic impact of new U.S. tariffs, which led to what the Wall Street Journal described as “one of the wildest weeks in market history” following their April 2 announcement. Despite tariff-related pressures, inflation has slowed more than expected, with the Consumer Price Index increasing just 2.3% year-over-year as of April – its lowest rate since 2021.

The Federal Reserve has adopted a “wait and see” approach, holding interest rates steady at 4.25% to 4.5%, with JPMorgan Chase strategists predicting potential rate cuts in the second half of the year.

Sector Analysis Reveals Mixed Outlook

EquityMultiple’s analysis highlights varying impacts across commercial real estate sectors:

• Industrial emerges as a “bright spot,” with Moody’s projecting 3% annual rent growth in 2025-2026-the highest among major CRE property types

• Multifamily may benefit from reduced new construction competition in the future, with improved fundamentals including lower vacancy rates and rising rents

• Office shows signs of recovery with 39% higher transaction volumes year-over-year in Q1 according to CoStar, driven by return-to-office mandates

• Retail remains “remarkably stable” despite some retailer sentiment concerns following tariff announcements

Geographic Performance Varies Widely

The report identifies significant regional variations, with New York posting over 1 million square feet of positive office absorption and Dallas-Fort Worth leading in both retail and industrial absorption. Conversely, Los Angeles lost 3.1 million square feet of retail space, which reflects broader e-commerce trends.

Investor Sentiment Remains Cautiously Optimistic

According to EquityMultiple’s investor survey data included in the report, a plurality of investors feel “about the same” about their portfolios versus last year and plan to maintain similar investment levels, suggesting measured confidence despite market uncertainty.

Strategic Recommendations Emphasize Diversification

The outlook reinforces EquityMultiple’s long-standing emphasis on diversification across asset classes and geographic markets. It underscores that diversification and understanding risk tolerance are the key strategies for navigating the current fast-moving environment, particularly as global trade disruptions and policy uncertainty create both challenges and opportunities for long-term investment.

EquityMultiple continues to offer investors access to commercial real estate opportunities across its three investment pillars – Keep, Earn, and Grow – spanning multiple asset classes and markets through partnerships with vetted sponsors nationwide. The platform was recently recognized as the “Best Real Estate Crowdfunding Site for Transparency” by Investopedia.

About EquityMultiple

EquityMultiple’s mission is to guide investors toward a stronger, more diversified portfolio. EquityMultiple brings accredited investors curated real estate private equity and private credit offerings, broadening and streamlining access to CRE. Founded in 2015, EquityMultiple has completed 250 transactions totaling over $21 billion in total capitalization across 142 markets nationwide. For more information, visit equitymultiple.com.

Contact Information

Daniel Brereton
press@equitymultiple.com
+16468449918

SOURCE: Equity Multiple Inc

View the original press release on ACCESS Newswire